PE-22-28: A Dark Horse in Mood Regulation and Neuropharmacology

PE-22-28 is a synthetic heptapeptide with the sequence Gly-Val-Ser-Trp-Gly-Leu-Arg (GVSWGLR). It's a truncated, optimized fragment derived from spadin — an endogenous protein cleaved from sortilin that antagonizes the TREK-1 channel.

Veyssiere et al. (2014) showed that retro-inverso analogs of spadin retain antidepressant-like activity while improving stability and potency. PE-22-28 sits in this optimized-fragment class and is widely used as the cleaner research-tool version of the parent peptide.

Under baseline conditions, the TREK-1 (TWIK-related K+ channel 1) channel acts as a brake on serotonergic neurons in the raphe nuclei. By allowing potassium ions to flow out of the cell, it hyperpolarizes the neuron and makes it less likely to fire — suppressing serotonin release.

PE-22-28 binds and selectively blocks TREK-1. With the brake released, serotonergic neurons increase their firing rate and serotonin availability rises in the hippocampus, the limbic system, and the prefrontal cortex.

Unlike SSRI-class molecules, which work "downstream" by blocking serotonin reuptake at the synaptic cleft, PE-22-28 works "upstream" at the ion-channel level. That difference is the leading hypothesis for why preclinical models show effects in hours rather than the multi-week receptor-adaptation window of SSRIs.

Because of its high selectivity, PE-22-28 is a powerful tool in neuroscience research across three converging investigation tracks.

Neurogenesis and synaptogenesis: studies have shown that administration increases hippocampal neurogenesis (the birth of new neurons) and levels of PSD-95, a postsynaptic scaffolding protein essential for synaptic stability and communication.

Stress resilience: researchers use PE-22-28 to study how to interrupt stress-induced serotonin suppression. It has demonstrated efficacy in rodent behavioral models including decreased immobility in the forced-swim test and reduced latency-to-feed in novelty-suppressed feeding tests.

Ischemia and neuroprotection: emerging research suggests that by blocking TREK-1, PE-22-28 may reduce apoptotic (programmed) cell death in certain conditions, including stroke-induced brain injury models.

The standard way to characterize PE-22-28's efficacy is the whole-cell patch-clamp technique (Veyssiere et al., 2014). By expressing TREK-1 in HEK-293 cell lines, researchers can record the potassium current and observe how effectively the compound blocks the channel across concentrations.

Dose-response curves are then used to compute the IC50 — the half-maximal inhibitory concentration — and compare potency against the parent spadin peptide. Patch-clamp configurations also confirm that the inhibition is specific to TREK-1 rather than a broader membrane-disruption effect.

PE-22-28 is an experimental research compound. Its safety profile in humans has not been established through large-scale clinical trials. The compound is not FDA-approved for human use and is sold for in vitro and laboratory research only.

In animal and pilot studies, reported biological signals of interest include enhanced hedonic tone, more stable mood baselines, and improvements in stress tolerance. Reported handling-side risks across peptide research include injection-site reactions, systemic allergic sensitivity, and transient metabolic / endocrine shifts.

All Revitalized research compounds are sold strictly for research use. Not for human consumption, diagnostic, or therapeutic use. Standard institutional biosafety guidelines apply.

Mazella, J., Pétrault, O., Lucas, G., Deval, E., Béraud-Dufour, S., Gandin, C., et al. (2010). Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: A new concept in the antidepressant drug design. PLoS Biology, 8(4), e1000355.

Veyssiere, J., Moha ou Maati, H., Mazella, J., Gaudriault, G., Moreno, S., Heurteaux, C., & Borsotto, M. (2014). Retroinverso analogs of spadin display increased antidepressant effects. Psychopharmacology, 232(3), 561–574.

Shah, B., Sindhikara, D., Borrelli, K., & Leffler, A. E. (2020). Water thermodynamics of peptide toxin binding sites on ion channels. Toxins, 12(10), 652.